Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine
Phase III Study of ASP7374 -Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Elderly Subjects
Sponsor: UMN Pharma Inc.
Listed as NCT01767896, this PHASE3 trial focuses on Influenza and remains completed. Sponsored by UMN Pharma Inc., it has been updated 7 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Oct 2017 [monthly]
Completed PHASE3
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UMN Pharma Inc.
For direct contact, visit the study record on ClinicalTrials.gov .